A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy

Phase 2

• Conditions: Advanced or recurrent esophageal cancer

• Registration Number: JPRN-UMIN000019230
• Lead Sponsor: niversity of Miyazaki Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-10-13
• Study Completion: 2020-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

1)Pregnant or lactating women 2)Symptomatic brain metastasis 3)Synchronous or metachronous (within 5 years) malignancies except for mucosal tumors of gastrointestinal tract 4)Severe complications (serious cerebrovascular disorders, uncontrollable hypertension, uncontrollable diabetes mellitus, active ulceration) 5)Active bacterial or fungous infection 6)Interstitial pneumonitis or pulmonary fibrosis 7)Massive pleural effusion or massive ascites 8)Past histrory of myocardial infarction and angina attack within 6 months 9)Past histrory of congested heart failure 10)Arhythmia requiring treatment 11)Peripheral neuropathy grade >=2 by CTCAE v4.0 12)With a history of allergic reaction to polyoxyethylene castor oil or hydrogenated castor oil 13)Serious psychiatric disease 14)Systemic steroids medication

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response rate

Secondary Outcome Measures

Name	Time	Method
Overall survival, progression-free survival, adverse events